Table 5 Diagnostic performance of individual biomarker candidates and their combination in distinguishing between NM-CRC and M-CRC patients in the study- and validation-cohorts.

FN

0.510 (0.245–0.775)

30

90

0.661 (0.462–0.860)

20

93

C9

0.730 (0.496–0.964)

60

90

0.616 (0.408–0.824)

63

71

LRG

0.660 (0.405–0.915)

70

70

0.558 (0.343–0.773)

56

71

A1AT

0.550 (0.283–0.817)

80

50

0.580 (0.370–0.791)

44

86

AGP1*

0.790 (0.567-1.00)

70

100

0.866 (0.727-1.000)

75

93

S100A8

0.510 (0.205–0.815)

100

50

0.758 (0.554–0.962)

67

80

FN + A1AT + AGP1**

0.920 (0.800-1.000)

80

90

0.875 (0.740-1.000)

81

93

C9 + FN1 + AGP1*

0.810 (0.598-1.000)

70

90

0.884 (0.746-1.000)

88

93

LRG + FN + AGP1*

0.840 (0.664-1.000)

70

90

0.911 (0.809-1.000)

94

78

C9 + FN + A1AT*

0.810 (0.601-1.000)

70

90

0.755 (0.577–0.933)

75

79

LRG + FN + A1AT

0.730 (0.496–0.964)

80

70

0.705 (0.515–0.896)

44

93

LRG + C9 + FN

0.770 (0.549–0.992)

60

90

0.688 (0.495–0.880)

50

86

LRG + C9 + A1AT

0.870 (0.678-1.000)

60

90

0.674 (0.477–0.872)

94

43

LRG + C9 + AGP1*

0.820 (0.633-1.000)

70

90

0.906 (0.798-1.000)

81

93

LRG + A1AT + AGP1***

0.940 (0.840-1.000)

90

90

0.897 (0.784-1.000)

81

93

C9 + A1AT + AGP1**

0.910 (0.783-1.000)

80

90

0.880 (0.744-1.000)

81

93